Enjoy complimentary customisation on priority with our Enterprise License!
This pipeline analysis report provides detailed insights into the clinical trials landscape of COVID-19 therapeutics, including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration (RoA), target, mechanism of action (MoA), and therapeutic modalities. Furthermore, the report provides an analysis of the companies currently involved in the development of pipeline molecules for COVID-19 including AbbVie Inc., AIM ImmunoTech Inc., Ansun BioPharma, APEIRON Biologics AG, Ascletis Pharma Inc., Blade Therapeutics Inc., Can-Fite BioPharma Ltd., CanSino Biologics Inc., Clover Biopharmaceuticals, F. Hoffmann-La Roche Ltd., FUJIFILM Corp., Gilead Sciences Inc., IMV Inc., InflaRx GmbH, Inovio Pharmaceuticals Inc., and Johnson & Johnson Services Inc.
The COVID-19 pandemic started in China in the last quarter of 2019 and spread globally by early 2020. Globally, the incidence and prevalence of COVID-19 are increasing aggressively. According to the Worldometers.info report, updated on April 13, 2020, the number of COVID-19 cases reported was 1,862,254, out of which 6.17% of the people have lost their lives, and about 23.18% people have been recovered globally.
Coronavirus disease (COVID-19) is infectious and is caused by a new coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the people affected with COVID-19 experience mild-to-moderate respiratory illness and recover without requiring special treatment. However, older people and people with certain medical conditions, including cardiovascular diseases, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness. Currently, there are no specific vaccines or treatments for COVID-19. However, owing to the above-mentioned factors, many ongoing clinical trials are evaluating potential treatments, especially target molecules for the immune system. Over 26% of the molecules in the pipeline are currently in the pre-clinical stages.
Several companies are involved in the development of pipeline molecules for COVID-19. In addition to the companies, major institutes, universities, and hospitals are also conducting studies on COVID-19. Moreover, companies are collaborating with institutions such as the US Department of Health & Human Services and the University of British Columbia to use the available technologies properly for the further development and commercialization of molecules.
The report covers detailed information on several companies actively involved in the development of molecules for COVID-19 including -
Most of the pipeline molecules for COVID-19 treatment are being developed for oral administration. Additionally, companies and institutions are also focusing on developing drugs that can be delivered through the subcutis (intravenous RoA).
Monotherapy uses a single drug to treat a disorder. Over 64% of the molecules that are currently in the pipeline to treat COVID-19 are being developed as monotherapy drugs.
We can help! Our analysts can customize this report to meet your requirements. Get in touch
PART 01: Executive Summary
PART 02: Scope
PART 03: Disease overview
PART 04: Regulatory framework
PART 05: Drug development landscape
PART 06: Drug development strategies
PART 07: Recruitment strategies
PART 08: Key companies
PART 09: AbbVie Inc.
PART 10: AIM ImmunoTech Inc.
PART 11: Ansun BioPharma
PART 12: APEIRON Biologics AG
PART 13: Ascletis Pharma Inc.
PART 14: Blade Therapeutics Inc.
PART 15: Can-Fite BioPharma Ltd.
PART 16: CanSino Biologics Inc.
PART 17: Clover Biopharmaceuticals
PART 18: F. Hoffmann-La Roche Ltd.
PART 19: FUJIFILM Corp.
PART 20: Gilead Sciences Inc.
PART 21: IMV Inc.
PART 22: InflaRx GmbH
PART 23: Inovio Pharmaceuticals Inc.
PART 24: Johnson & Johnson Services Inc.
PART 25: Mallinckrodt Plc
PART 26: Moderna Inc.
PART 27: NeuroRx Inc.
PART 28: Novavax Inc.
PART 29: OncoImmune Inc.
PART 30: OyaGen Inc.
PART 31: Pulmotect Inc.
PART 32: RedHill Biopharma Ltd.
PART 33: Regeneron Pharmaceuticals Inc.
PART 34: Sanofi
PART 35: SLA Pharma AG
PART 36: Sorrento Therapeutics Inc.
PART 37: Swedish Orphan Biovitrum AB
PART 38: Symvivo Corp.
PART 39: Takeda Pharmaceutical Co. Ltd.
PART 40: Tonix Pharmaceuticals Holding Corp.
PART 41: Vanda Pharmaceuticals Inc.
PART 42: Vaxart Inc.
PART 43: Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.